Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs

被引：0
|
作者：
Zhang, Yi-Chen
Pi, Can
Ke, E-E
Chen, Zhi-Hong
Su, Jian
Dong, Zhong-Yi
Xu, Chong-Rui
Tu, Hai-Yan
Yan, Hong-Hong
Zhong, Wen-Zhao
Yang, Jin-Ji
Zhang, Xu-Chao
Wu, Yi Long
Zhou, Qing
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] GGH, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Acquired resistance; EGFR TKIs; spatiotemporal heterogeneity; T790M;
D O I：
10.1016/j.jtho.2016.11.1762
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-095
引用
收藏
页码：S1249 / S1249
页数：1
相关论文
共 50 条
  • [41] Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M
    Soucheray, Margaret
    Capelletti, Marzia
    Pulido, Ines
    Kuang, Yunan
    Paweletz, Cloud P.
    Becker, Jeffrey H.
    Kikuchi, Eiki
    Xu, Chunxiao
    Patel, Tarun B.
    Al-shahrour, Fatima
    Carretero, Julian
    Wong, Kwok-Kin
    Janne, Pasi A.
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    CANCER RESEARCH, 2015, 75
  • [42] Role of T790M Mutation in EGFR-TKI Rechallenge for Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Zhang, Qiu-Yi
    Ke, E-E
    Deng, Wei
    Niu, Fei-Yu
    Zhao, Ning
    Su, Jian
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Xu, Chong-Rui
    Yan, Hong-Hong
    Wu, Yi-Long
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S271 - S271
  • [43] Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
    Bin Zou
    Victor H. F. Lee
    Lijiang Chen
    Lichun Ma
    Debby D. Wang
    Hong Yan
    Scientific Reports, 7
  • [44] Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
    Zou, Bin
    Lee, Victor H. F.
    Chen, Lijiang
    Ma, Lichun
    Wang, Debby D.
    Yan, Hong
    SCIENTIFIC REPORTS, 2017, 7
  • [45] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [46] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
    Huang, Chun-Ta
    Lin, Chih-An
    Su, Te-Jen
    Yang, Ching-Yao
    Tsai, Tzu-Hsiu
    Hsu, Chia-Lin
    Liao, Wei-Yu
    Chen, Kuan-Yu
    Ho, Chao-Chi
    Yu, Chong-Jen
    BMC CANCER, 2023, 23 (01)
  • [47] Identification of Novel Mutations by High-Throughout Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs
    Li, C.
    Zhang, B.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S981 - S981
  • [48] Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
    Li, Xuefei
    Cai, Weijing
    Yang, Guohua
    Su, Chunxia
    Ren, Shengxiang
    Zhao, Chao
    Hu, Rongjun
    Chen, Xiaoxia
    Gao, Guanghui
    Guo, Zhiwei
    Li, Wei
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) : 1388 - 1397
  • [49] Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
    Zeng, Yue
    Feng, Yuanqing
    Fu, Guihua
    Jiang, Junlan
    Liu, Xiaohan
    Pan, Yue
    Hu, Chunhong
    Liu, Xianling
    Wu, Fang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance
    Taube, Erika
    Jokinen, Elina
    Koivunen, Peppi
    Koivunen, Jussi P.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (04) : 970 - 979
12345